docetaxel anhydrous has been researched along with cilengitide in 1 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 194 | 29 | 133 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | cilengitide (IC50) |
|---|---|---|---|
| Integrin beta-3 | Homo sapiens (human) | 0.3087 | |
| Integrin beta-1 | Homo sapiens (human) | 1.0131 | |
| Integrin alpha-V | Homo sapiens (human) | 0.514 | |
| Integrin alpha-IIb | Homo sapiens (human) | 2.399 | |
| Integrin alpha-5 | Homo sapiens (human) | 0.9006 | |
| Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Integrin beta-5 | Homo sapiens (human) | 0.4791 | |
| Integrin beta-6 | Homo sapiens (human) | 4.042 | |
| Alpha-1D adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0005 | |
| Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0005 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cardenal, F; Eckmayr, J; Kerber, A; Manegold, C; Schuette, W; Ulsperger, E; Vansteenkiste, J; von Pawel, J; Woll, PJ | 1 |
1 trial(s) available for docetaxel anhydrous and cilengitide
| Article | Year |
|---|---|
Randomized phase II study of three doses of the integrin inhibitor cilengitide versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Humans; Integrins; Lung Neoplasms; Male; Middle Aged; Snake Venoms; Taxoids | 2013 |